FleetPulse | $11,000,000 | (May 10, 2024)
ArkeaBio™ | $26,500,000 | (May 10, 2024)
Bluejay Therapeutics | $182,000,000 | (May 10, 2024)
Antiva Biosciences, Inc.
United States
- South San Francisco, California
- 27/04/2023
- Series E
- $53,000,000
Antiva Biosciences, Inc. is a clinical stage biopharmaceutical company developing novel, topical therapeutics for the treatment of diseases caused by HPV infection. We aim to stop cancer before it starts by treating the pre-cancerous lesions caused by HPV. Our lead programs are in clinical trials in high grade anal intraepithelial neoplasias (AIN 2,3) and high grade cervical intraepithelial neoplasias (CIN 2,3).
The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego and builds on his anti-viral expertise as co-founder of Triangle Pharmaceuticals and Chimerix. Antiva’s chemistry platform has yielded over two hundred proprietary pro-drug compounds that are designed to enhance the therapeutic index of known, potent antivirals.
- Industry Biotechnology Research
- Website https://antivabio.com/
- LinkedIn https://www.linkedin.com/company/antiva-biosciences-inc/people/
Related People
Karl HostetlerFounder
United States -
San Diego County, California
Medical Specialties: Board Certified Internal Medicine and Endocrinology & Metabolism
Medicinal Chemistry
Translational Research
Drug Discovery
Antiviral drugs
CoverTree | $13,000,000 | (May 10, 2024)
Li Industries | $36,000,000 | (May 10, 2024)
Archive Intel | $1,000,000 | (May 10, 2024)
Little Sparrows Technologies | $3,000,000 | (May 10, 2024)
Triomics | $15,000,000 | (May 10, 2024)
Altera | $9,000,000 | (May 10, 2024)
Electricity Maps | $5,390,775 | (May 10, 2024)
Sift Healthcare | $20,000,000 | (May 10, 2024)
Aardvark Therapeutics | $85,000,000 | (May 10, 2024)
Chip City | $7,500,000 | (May 10, 2024)